Marc Abramowicz

Marc Abramowicz (ORCID : 0000-0003-0623-8768) is a clinical and molecular geneticist who moved from Université Libre de Bruxelles (ULB), Belgium, to Geneva UNIGE and HUG in early 2018. Beyond his recognized expertise in clinical syndromology and molecular genetics, he has a proven track record in gene identification and characterization, initially in the field of molecular endocrinology and later in brain developmental disorders. His research has been funded over 20 years without discontinuation by competitive grants, including the Belgian FNRS and European ERA-Net. His group has produced seminal discoveries in the field of inherited disorders of the thyroid and in the field of primary microcephaly, and has recently produced the first GWAS in renal graft rejection. His interest in potential clinical applications of ASOs has been longstanding. In 2001 Marc and his team published recommendations for reliable evaluation, and their own study of in vitro efficacy of Chimeraplast, a form of DNA/RNA hybrid oligonucleotide (Albuquerque-Silva et al. 2001). He has published 124 scientific papers in peer-reviewed journals (Web of Science H-index = 37; Google Scholar H-index = 45). March 2020.